Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What???
Added more Friday. 10 min finger prick test beats the hell out of the nasal swab test, which takes about two weeks to get results. Rapid tests are the way to go!
Amazed this board is so quiet on this ticker. It has been hopping on ST for a month now. $10 coming soon.
Same here- almost forgot about my holdings.
?? moving again? About stinking time! The news bodes well, so let’s head to penny land!
I haven’t had this much fun since CODX blew up. Congrats all longs!!!
Added more pre market. Thursday AH will be very interesting!
Yeah, we got screwed. I had 2 million shares. Would have been sweet at $7.
Docj- Thanks for posting DD for us. Much appreciated.
One of the few green tickers in a sea of red this morning.
Interesting AH moves! Wish I had my pre-RS shares at $4.95!
Doing great today with the acquisition news. Zacks target price $3. Would like to see it hit $2 by Friday; needs more volume.
Nice morning move up! Break the wall at $3.50
Can’t wait for the merger PR in June. Patiently waiting...
Expecting an upswing because they are presenting at the Jeffries Virtual Global Healthcare Conference on Tuesday, June 2.
Offering now closed; should be ready to roll tomorrow morning.
Moving AH!
1)New CMS approved 64 billing codes.
2) May 12, 2020 04:18 PM ET (BZ Newswire) -- Earnings
IsoRay (AMEX:ISR) reported quarterly losses of $(0.010) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.020) per share from the same period last year. The company reported quarterly sales of $2.880 million which beat the analyst consensus estimate of $2.550 million by 12.94 percent. This is a 49.69 percent increase over sales of $1.924 million the same period last year.
About time! I’ve been holding so long that moss grew on my shares.
$1.28 would be sweet! Too bad this doesn’t have a CV play angle. It would fly then.
Watching for $5
Watching for continued movement this week. From Benzinga on March 5: “The company, though it has not disclosed any COVID-19 development, has a vaccine adjuvant in the works.
Its SA-702's immune activity is being harnessed to enhance the efficacy of vaccines by eliciting a stronger immune response to a vaccine's particular antigen.”
Added a little more this morning. Potential positive catalysts ahead.
Yep. FOMO will drive it. GLTA
Obviously the seasonal flu kills thousands each year. Covid-19, however, has spread to every continent except Antarctica, making it a pandemic. Not your typical flu.
Despite your “it is just a flu bug, nothing to see here” stance, I hope you do not get Covid-19.
It isn’t the flu that is killing the people, it is the ARDS that follows. Accute Respiratory Distress Syndrome is a killer, and it doesn’t matter how old you are. Not everyone who gets Covid-19 develops ARDS, but an increasing number of people are, and no one knows what causes it in certain people and not others. That is the biggest problem right now.
The vaccine still needs to go through human trials, and it won’t be days- it will be months even when sped up. There are several trial phases. Best case scenario phase 1 trials in April and the phase 2 trials in July.
Please do your DD on this and don’t rely solely on strangers on a message board. Look to NIH and CDC for current info on time frame.
NIH timeline info from 2/26/20:
https://thehill.com/policy/healthcare/public-global-health/484702-health-official-says-coronavirus-vaccine-will-take-at
No worries!
.001 new HOD at 2:51
Bodes well, IMO.
Agreed.
?? Interesting turn of events after all this time.
I hope it holds! Currently $9.74 at 8:13 am in NY.
Lots of catalysts coming- very positive outlook. Adding to my position!
GLTA! $ONCY$
Looking better after hours.
Great run up today! HOD so far $4.43.
Raymond James analyst David Novak upgrades Leap Therapeutics (NASDAQ:LPTX) from Market Perform to Outperform and announces $2.5 price target.
Nice pre market move to $6.59. PR released with VRNA appointing David Moskowitz as VP, Capital Markets Strategy and Investor Relations.
Hoping the rumor of good news is true. Enjoying the upward trend!
GLTA!
Moving up a little this morning. Watching volume.
Their loss!
Congrats for hanging in here!
$4 printed. Looks like a good morning here!
GLTA. $ONCY$